A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibod...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828050/
https://ncbi.nlm.nih.gov/pubmed/23922187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28299
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki